D
Daniel Shasha
Researcher at Beth Israel Medical Center
Publications - 41
Citations - 1407
Daniel Shasha is an academic researcher from Beth Israel Medical Center. The author has contributed to research in topics: Cancer & Epoetin alfa. The author has an hindex of 14, co-authored 37 publications receiving 1349 citations. Previous affiliations of Daniel Shasha include Yeshiva University & Beth Israel Deaconess Medical Center.
Papers
More filters
Journal ArticleDOI
Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
Matthew R. Smith,James A. Eastham,Donald M. Gleason,Daniel Shasha,Simon Tchekmedyian,Norman Zinner +5 more
TL;DR: In this paper, a multicenter double-blind, randomized, placebo controlled clinical trial was performed to assess the effect of zoledronic acid, a potent new bisphosphonate, on bone mineral density during androgen deprivation therapy for nonmetastatic prostate cancer.
Journal ArticleDOI
Cancer-Related Anemia: Pathogenesis, Prevalence and Treatment
Gunnar Birgegård,Matti S. Aapro,Carsten Bokemeyer,Mario Dicato,Peter Drings,Javier Hornedo,Maciej Krzakowski,Heinz Ludwig,Sergio Pecorelli,Hans J. Schmoll,Maurice Schneider,Dirk Schrijvers,Daniel Shasha,Simon Van Belle +13 more
TL;DR: Findings are noteworthy, since a growing body of clinical evidence indicates that the treatment of anemia can significantly improve patients’ quality of life and may also improve the clinical outcome.
Journal ArticleDOI
The American Brachytherapy Society recommendations for brachytherapy of soft tissue sarcomas
TL;DR: Brachytherapy represents an effective means of enhancing the therapeutic ratio, offering both biologic and dosimetric advantage in the treatment of patients with soft tissue sarcoma.
Journal ArticleDOI
Prevalence of anemia in cancer patients undergoing radiation therapy.
Louis B. Harrison,Daniel Shasha,Lauren Shiaova,Carol White,Beverly Ramdeen,Russell K. Portenoy +5 more
TL;DR: Data show that anemia is widespread among patients seen in radiation oncology practices, and strategies to reverse anemia should receive greater attention.
Journal ArticleDOI
Prophylactic sildenafil citrate improves select aspects of sexual function in men treated with radiotherapy for prostate cancer.
Michael J. Zelefsky,Daniel Shasha,Rebekah Dunn Branco,Marisa A. Kollmeier,Raymond E. Baser,Xin Pei,Ronald D. Ennis,Richard G. Stock,Natan Bar-Chama,John P. Mulhall +9 more
TL;DR: This is the largest randomized, prospective, controlled trial to show the usefulness of a phosphodiesterase-5 inhibitor as a rehabilitation strategy in patients with prostate cancer who received radiation therapy.